Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00887146 · ClinicalTrials.gov registry record · Phase 3

Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma

A Phase 3 study of Brain and Central Nervous System Tumors, sponsored by Alliance for Clinical Trials in Oncology.

Active
Registry status
Phase 3
Development phase
305
Enrollment target
20
Study locations

NCT00887146 is a Phase 3 study of Brain and Central Nervous System Tumors that is active but no longer recruiting, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 305 participants, above the 177-participant average among 45 other Brain and Central Nervous System Tumors trials with a reported enrollment target (72% higher). The trial reports 20 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00887146, a Phase 3 study of Brain and Central Nervous System Tumors, is active but no longer recruiting, sponsored by Alliance for Clinical Trials in Oncology.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
305 participants
Enrollment target
20
Study locations

Study Summary

Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving radiation with concomitant and adjuvant temozolomide versus radiation with adjuvant PCV is more effective in treating anaplastic glioma or low grade glioma.

Interventions

  • RADIATION radiotherapy
  • DRUG concomitant temozolomide (TMZ)
  • DRUG procarbazine
  • DRUG adjuvant temozolomide (TMZ)
  • DRUG CCNU

Study Locations (20)

California

  • Kaiser Permanente-Anaheim - Anaheim
  • Sutter Cancer Centers Radiation Oncology Services-Auburn - Auburn
  • Mills-Peninsula Medical Center - Burlingame
  • Sutter Cancer Centers Radiation Oncology Services-Cameron Park - Cameron Park
  • Community Cancer Institute - Clovis
  • University Oncology Associates - Clovis
  • UC San Diego Moores Cancer Center - La Jolla
  • Kaiser Permanente Los Angeles Medical Center - Los Angeles
  • Cedars Sinai Medical Center - Los Angeles

Alaska

  • Anchorage Associates in Radiation Medicine - Anchorage
  • Alaska Oncology and Hematology LLC - Anchorage
  • Alaska Women's Cancer Care - Anchorage
  • Anchorage Oncology Centre - Anchorage
  • Katmai Oncology Group - Anchorage
  • Providence Alaska Medical Center - Anchorage

Arizona

  • Saint Joseph's Hospital and Medical Center - Phoenix
  • Arizona Oncology-Deer Valley Center - Phoenix
  • Arizona Oncology Services Foundation - Scottsdale

Alabama

  • University of Alabama at Birmingham Cancer Center - Birmingham
  • Providence Hospital - Mobile

Trial Details

FieldValue
Enrollment Target 305 participants
Start Date 2009-09
Est. Completion 2029-10-31
Phase Phase 3

What the Registry Record Tells You About NCT00887146

The ClinicalTrials.gov registry entry for NCT00887146 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 305 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 177-participant average among 45 other Brain and Central Nervous System Tumors trials with a reported enrollment target (72% higher). The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Brain and Central Nervous System Tumors appearing as the primary indexed condition, and to 5 interventions - of which radiotherapy is the first listed.

NCT00887146 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Alaska, Arizona.

Frequently Asked Questions

What is clinical trial NCT00887146 about?

NCT00887146 is a clinical study titled "Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma". Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving radiation with concomitant and ...

What is the current status of trial NCT00887146?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 305 participants. The study started on 2009-09. Estimated completion is 2029-10-31.

What conditions does trial NCT00887146 study?

This clinical trial studies the following conditions: Brain and Central Nervous System Tumors.

What interventions are being tested in trial NCT00887146?

The interventions under investigation include: radiotherapy (RADIATION), concomitant temozolomide (TMZ) (DRUG), procarbazine (DRUG), adjuvant temozolomide (TMZ) (DRUG), CCNU (DRUG).

Who is sponsoring clinical trial NCT00887146?

This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00887146 being conducted?

This trial has 20 study locations across Alabama, Alaska, Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Brain and Central Nervous System Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.